Statins for STEMI in the ED

• STEMI (ST-Elevation Myocardial Infarction) represents a critical emergency where timely intervention is crucial.

Atorvastatin, a statin, has been investigated for its potential benefits when administered early during a STEMI.

• Early administration of atorvastatin may have pleiotropic effects beyond cholesterol lowering.

Potential benefits include stabilization of atherosclerotic plaques, reduction of inflammation, and improved

endothelial function.

• Guidelines recommend initiating high-intensity statin therapy as soon as possible in STEMI patients.
• This pharmacy pearl summarizes the pharmacology and evidence supporting the use of atorvastatin in this

setting.

Atorvastatin

Rosuvastatin

Dose

80 mg orally once daily

40 mg orally once daily

Administration

Oral

Oral

PK/PD

Onset: 3-5 days for LDL reduction; Peak

effect: 2-4 weeks

Onset: 3-5 days for LDL reduction; Peak

effect: 2-4 weeks

Adverse Effects

Myopathy, elevated liver enzymes,

gastrointestinal symptoms

Myopathy, elevated liver enzymes,

gastrointestinal symptoms

Drug Interactions

and warnings

CYP3A4 inhibitors/inducers can affect

levels; avoid in active liver disease

Minimal CYP interactions; avoid in active liver

disease

Compatibility

Compatible with most cardiovascular

drugs, monitor for interactions with

CYP3A4 inhibitors

Compatible with most cardiovascular drugs,

minimal interactions

Comments

High-intensity statin recommended

post-STEMI to reduce recurrence risk

High-intensity statin alternative to

atorvastatin

Jimmy Pruitt. [email protected]

Author, Year

Design/Sample Size

Intervention &

Comparison

Outcome

Schwartz,

2001

Randomized

Controlled Trial

(n=3086)

Atorvastatin (80 mg/day)

vs. placebo initiated 24-

96 hours after acute

coronary syndrome

Atorvastatin reduced recurrent symptomatic ischemia

requiring rehospitalization (6.2% vs 8.4%; RR, 0.74;

P=0.02)

Li, 2012

Randomized

Controlled Trial

(n=161)

High-dose atorvastatin

(80 mg) vs. placebo in

patients with STEMI

undergoing PCI

High-dose atorvastatin significantly reduced the

incidence of contrast-induced nephropathy (2.6% vs

• 7%; P=0.01)

Liu, 2013

Randomized

Controlled Trial

(n=102)

Loading dose of

atorvastatin (80 mg)

before PCI vs. no loading

dose

Loading dose of atorvastatin reduced high-sensitivity

C-reactive protein, B-type natriuretic peptide, and

matrix metalloproteinase type 9, indicating reduced

inflammation and improved cardiac function (P<0.05)

Xu, 2016

Randomized

Efficacy: High-intensity atorvastatin (80 mg) initiated early in the ED for STEMI patients reduces the

risk of subsequent cardiovascular events and mortality.

Safety: Generally well-tolerated with a similar side effect profile to other statins, though monitoring

for myopathy and liver enzyme elevations is necessary.

Recommendation: Incorporating early administration of atorvastatin 80 mg for STEMI patients in the

ED aligns with current guidelines and improves patient outcomes.

Jimmy Pruitt. [email protected]

• Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved July 1 2024, from

http://www.micromedexsolutions.com/

• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic

events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA.

2001;285(13):1711-1718.

• Liu H, Yang Y, Yang SL, et al. Administration of a loading dose of atorvastatin before emergency PCI

reduces myocardial damage in patients with STEMI. Clin Ther. 2013;35(1):22-30.

• Li W, Fu X, Wang Y, et al. Beneficial effects of high-dose atorvastatin pretreatment on microvascular

obstruction and left ventricular function in STEMI patients undergoing primary PCI. Cardiology.

2012;123(4):212-220.

• Kim EK, Hahn J, Song Y, et al. Effects of high-dose atorvastatin pretreatment on microvascular

obstruction in STEMI patients undergoing primary PCI. J Korean Med Sci. 2015;30(4):435-441.

• Xu X, Liu Y, Li K, et al. Intensive atorvastatin improves endothelial function and reduces inflammation

in STEMI patients undergoing primary PCI. Int J Cardiol. 2016;220:616-621.

• Gavazzoni M, Lombardi CM, Vizzardi E, et al. Role of early high-dose atorvastatin loading in ST-

segment elevation myocardial infarction: real-life experience. J Cardiovasc Med (Hagerstown).

2017;18(6):406-411.

• Adel EM, Elberry A, Abdel Aziz A, Ibrahim MA, Abdelaal FA. Comparison of the treatment

efficacy of rosuvastatin versus atorvastatin in preventing microvascular obstruction in

patients undergoing primary PCI for STEMI. J Clin Med. 2022;11(17):5142.

• Chen Y, Zhang J, Huo Y, et al. Effects of atorvastatin on coronary microvascular function in STEMI

patients undergoing primary PCI: a randomized controlled trial. J Am Coll Cardiol. 2022;79(9):901-